LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial

Ethical guidelines for publishing in the journal of cachexia, sarcopenia and muscle: update 2017

(2017) Stephan von Haehling et al.   Journal of Cachexia Sarcopenia and Muscle

Molecular and neuroendocrine mechanisms of cancer cachexia

(2015) Maria Carolina S Mendes et al.   JOURNAL OF ENDOCRINOLOGY

Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting

(2015) R. C. Smith et al.   MOLECULAR CANCER THERAPEUTICS

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial

(2015) Clemens Becker et al.   Lancet Diabetes & Endocrinology

Pharmacological Inhibition of Myostatin and Changes in Lean Body Mass and Lower Extremity Muscle Size in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

(2014) Desmond Padhi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil and Radiotherapy for Locally Advanced Pancreatic Cancer: Final Results

(2013) Joseph M. Herman et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Understanding the mechanisms and treatment options in cancer cachexia

(2012) Kenneth Fearon et al.   Nature Reviews Clinical Oncology

Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice

(2011) Kate T. Murphy et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Definition and classification of cancer cachexia: an international consensus

(2011) Kenneth Fearon et al.   LANCET ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance

(2011) Sílvia Busquets et al.   Journal of Cachexia Sarcopenia and Muscle

A Phase II Study of Gemcitabine in Combination With Radiation Therapy in Patients With Localized, Unresectable, Pancreatic Cancer

(2010) Higinia R. Cardenes et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival

(2010) Xiaolan Zhou et al.   CELL

Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”

(2010) M. Muscaritoli et al.   CLINICAL NUTRITION

Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia

(2009) Margaret E. Benny Klimek et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Pancreatic cancerrelated cachexia: influence on metabolism and correlation to weight loss and pulmonary function

(2009) Jeannine Bachmann et al.   BMC CANCER

Randomized Double-Blind Phase II Trial Comparing Gemcitabine Plus LY293111 Versus Gemcitabine Plus Placebo in Advanced Adenocarcinoma of the Pancreas

(2009) Muhammad Wasif Saif et al.   CANCER JOURNAL

Mechanisms of Cancer Cachexia

(2009) Michael J. Tisdale   PHYSIOLOGICAL REVIEWS

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study

(2008) B. Chauffert et al.   ANNALS OF ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER